• Hamlet Biopharma raised a preliminary SEK 25.7 million from the exercise of TO5B warrants.
• Subscriptions covered 4,283,006 new B shares at SEK 6 per share; the preliminary exercise rate was about 79%.
• One transaction for 301,048 TO5B warrants remains unfinished for administrative reasons, covering SEK 1.81 million.
• If completed, the total proceeds would remain SEK 25.7 million before issue costs; total B shares would be 150,552,055.
• TO6B warrants outstanding total 6,976,744; exercise window runs Jan. 17–31, 2028 at SEK 10 per share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hamlet Biopharma AB published the original content used to generate this news brief via Cision (Ref. ID: 202608051037BITN____UKPR__SV_20260805-BIT-4662-0) on August 05, 2026, and is solely responsible for the information contained therein.